Format

Send to

Choose Destination
Medchemcomm. 2019 Jul 18;10(9):1646-1655. doi: 10.1039/c9md00234k. eCollection 2019 Sep 1.

Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.

Author information

1
Department of Biochemistry and Molecular Biophysics , Washington University School of Medicine , St. Louis , Missouri , USA . Email: janetkaj@wustl.edu ; Tel: +314 362 0509.
2
University of Wisconsin Carbone Cancer Center , Drug Development Core , University of Wisconsin-Madison , Madison , Wisconsin , USA.

Abstract

Matriptase and hepsin are type II transmembrane serine proteases (TTSPs). Along with related S1 trypsin like serine protease HGFA (hepatocyte growth factor activator), their unregulated proteolytic activity has been associated with cancer including tumor progression and metastasis. These three proteases have two substrates in common, hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), the ligands for MET and recepteur d'origine nantais (RON) receptor tyrosine kinases. Mechanism-based tetrapeptide and benzamidine inhibitors of these proteases have been shown to block HGF/MET and MSP/RON cancer cell signaling. Herein, we have rationally designed a new class of peptidomimetic hybrid small molecule piperidine carbamate dipeptide inhibitors comparable in potency to much larger tetrapeptides. We have identified multiple compounds which have potent activity against matriptase and hepsin and with excellent selectivity over the off-target serine proteases factor Xa and thrombin.

PMID:
31803403
PMCID:
PMC6844230
[Available on 2020-07-18]
DOI:
10.1039/c9md00234k

Supplemental Content

Full text links

Icon for Royal Society of Chemistry
Loading ...
Support Center